Vaccines for Immune-Mediated Diseases
Patients with safe interceded incendiary ailments (IMID, for instance, RA, IBD or skin problem, square measure at increased danger of contamination, partially in light-weight of the malady itself, but for the foremost half in light-weight of treatment with immune modulatory or immunological disorder medications. in spite of their raised hazard for immunisation preventable upset, the immunisation scope in IMID patients is shockingly low.
Related Conference of Vaccines for Immune-Mediated Diseases
March 20-21, 2024
7th International Conference on Vaccines, Immunology and Clinical Trials
Amsterdam, Netherlands
Vaccines for Immune-Mediated Diseases Conference Speakers
Recommended Sessions
- Bacterial Vaccines
- Cancer Vaccines & therapy
- Childhood & Maternal Vaccines
- DNA based mostly Vaccines
- HIV/AIDS Vaccines
- HPV & infectious disease Vaccines
- Immunizations & biological terrorism
- Modern Technologies in vaccinum Discovery & Development
- Plant-Derived Vaccines
- Protein-Based Vaccines
- Subunit vaccines
- Toxoid Vaccines
- Vaccines for Immune-Mediated Diseases
- Vaccines for Pregnant girls & Neonates
- Vaccines presymptomatic & Clinical Trials
Related Journals
Are you interested in
- Antiviral Therapies - Virology 2024 (Austria)
- Basic Immunology - Virology 2024 (Austria)
- Cancer Vaccines - Vaccine Congress 2024 (Spain)
- Challenges in Global Vaccination Programs - Vaccines R&D 2024 (Netherlands)
- Chicken pox Vaccines - Vaccine Congress 2024 (Spain)
- Clinical Immunology - Virology 2024 (Austria)
- Clinical Trials: Safety, Efficacy, and Beyond - Vaccines R&D 2024 (Netherlands)
- Component Vaccines - Vaccine Congress 2024 (Spain)
- COVID-19 Vaccine - Vaccine Congress 2024 (Spain)
- Cutting-Edge Techniques in Vaccine Manufacturing - Vaccines R&D 2024 (Netherlands)
- Ebola Vaccines - Vaccine Congress 2024 (Spain)
- Emerging Viral Diseases - Virology 2024 (Austria)
- Epidemiology and Public Health - Virology 2024 (Austria)
- Gene Editing for Vaccine Development - Vaccines R&D 2024 (Netherlands)
- HIV Vaccines - Vaccine Congress 2024 (Spain)
- Human Papilloma Virus Vaccine - Vaccine Congress 2024 (Spain)
- Immune System and Non-Infectious Diseases - Vaccines R&D 2024 (Netherlands)
- Immunogenetics and Genomics - Virology 2024 (Austria)
- Immunology and Infectious Diseases: Current Landscape - Vaccines R&D 2024 (Netherlands)
- Immunology of Aging and Vaccination - Vaccines R&D 2024 (Netherlands)
- Immunometabolism - Virology 2024 (Austria)
- Immunotherapy - Virology 2024 (Austria)
- Immunotherapy: Novel Strategies and Technologies - Vaccines R&D 2024 (Netherlands)
- Infectious Diseases and Immunity - Virology 2024 (Austria)
- Inflammation and Immune Response - Virology 2024 (Austria)
- Innovative Approaches to Vaccine Design - Vaccines R&D 2024 (Netherlands)
- MMR Vaccines - Vaccine Congress 2024 (Spain)
- Next-Generation Vaccines: Advancements and Challenges - Vaccines R&D 2024 (Netherlands)
- Polio Vaccines - Vaccine Congress 2024 (Spain)
- Precision Medicine and Personalized Vaccines - Vaccines R&D 2024 (Netherlands)
- Preclinical Vaccine Studies - Vaccine Congress 2024 (Spain)
- Public-Private Partnerships for Vaccine Research - Vaccines R&D 2024 (Netherlands)
- Regulatory Guidelines for Vaccine Approval - Vaccines R&D 2024 (Netherlands)
- The Future of Vaccinology: Trends and Prospects - Vaccines R&D 2024 (Netherlands)
- Vaccine Adjuvants - Vaccine Congress 2024 (Spain)
- Vaccine Development - Virology 2024 (Austria)
- Vaccine Hesitancy: Causes and Solutions - Vaccines R&D 2024 (Netherlands)
- Vaccine Regulatory Issues - Vaccine Congress 2024 (Spain)
- Vaccine Research & Development - Vaccine Congress 2024 (Spain)
- Vaccines Epidemiology - Vaccine Congress 2024 (Spain)
- Vaccines Immunology - Vaccine Congress 2024 (Spain)
- Viral Diagnostics - Virology 2024 (Austria)
- Viral Genomics and Evolution - Virology 2024 (Austria)
- Viral Immunology - Virology 2024 (Austria)
- Viral Pathogenesis - Virology 2024 (Austria)
- Viral Vaccines - Virology 2024 (Austria)